Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33(
|קרן||National Cancer Institute/NIH|
|פקולטה||Engineering, Exact Sciences, Life Sciences, Medicine|
This grant solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.
R33 applications are sought where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community.
Funding: $300,000 per year
Duration: 3 years
Research Authority due date: 10 days prior to submission
LOI (encouraged) due date: 1.2.23, 1.8.23
Full proposal due date: 1.3.23, 1.9.23
|עדכון אחרון||עדכון אחרון: 04/12/2022|